TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors
Open Access
- 16 October 2025
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 44 (1) , 187-202.e7
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (1S10OD024977-01)
- Parker Institute for Cancer Immunotherapy
This publication has 66 references indexed in Scilit:
- Clinical Importance of Clonal Hematopoiesis in Metastatic Gastrointestinal Tract CancersJAMA Network Open, 2023
- Clonal hematopoiesis and differential outcomes after immune checkpoint blockadeCancer Cell, 2022
- TET2-Driven Clonal Hematopoiesis and Response to CanakinumabJAMA Cardiology, 2022
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCancer Cell, 2020
- Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq2020
- Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid TumorsJAMA Oncology, 2018
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- edgeR for Differential RNA-seq and ChIP-seq Analysis: An Application to Stem Cell Biology2014
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationCancer Cell, 2010
- Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptorsImmunity, 1994